VYLOY Astellas Pharma Australia Pty Ltd
Product name
VYLOY
Accepted date
Dec-2023
Active ingredients
zolbetuximab
Proposed indication
Indicated for patients with human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.
Application type
A (new medicine)
Publication date
Dec-2023
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.